V A Khasanova | AMiner学者主页

全面呈现 [V A Khasanova] 的学术影响力

深度挖掘高质量成果与权威引用，让优秀看得见

研究兴趣

暂无数据

论文（12）

专利

基金项目

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

1Современная Стратегия Контроля За Гепатитом А: Опыт Проведения Плановой Вакцинации В Рамках Регионального Календаря Профилактических Прививок

И В Шахгильдян,М. И. Михайлов,О Н Ершова,П А Хухлович,В А Хасанова,И Н Лыткина,Н И Шулакова, В. В. Романенко,А И Юровских,А. А. Ясинский

2011Эпидемиология и вакцинопрофилактика

引用

AI阅读

2Is It Necessary to Vaccinate Children Against Hepatitis A Routinely in Present Time? the Evaluation of Results of Such Strategy of Hepatitis A Vaccine Prophylaxis in Selected Regions of the Russian Federation

I. V. Shakhgildian,M. I. Mikhailov,O. N. Ershova, P. A. Khukhlovitch,V. A. Khasanova,I. N. Lytkina,N. I. Shulakova,V. V. Romanenko, A. I. Yurovskih, A. A. Yasinskiy

Data about efficacy of conducting of routine vaccination of children against Hepatitis A are presented in the article. The results of realization such strategy of vaccine prevention of Hepatitis A in selected regions of Russian Federation are evaluated. The perspectives of using this experience in other regions of the country is discussed.

2011INFEKTSIYA I IMMUNITET（2011）

引用

AI阅读

3Современная Стратегия Контроля За Гепатитом А. Нужна Ли Сегодня Плановая Вакцинация Детей Против Этой Инфекции

И В Шахгильдян,П А Хухлович,О Н Ершова,В А Хасанова,Н. А. Сергеева,Л Е Кузина,Д М Брагинский,И Н Лыткина,Н И Шулакова, В. В. Романенко, В. В. Патлусова, Е. В. Сармометов,

2010Biological Products Prevention Diagnosis Treatment（2010）

引用

AI阅读

4НУЖНА ЛИ В НАСТОЯЩЕЕ ВРЕМЯ ПЛАНОВАЯ ВАКЦИНАЦИЯ ДЕТЕЙ ПРОТИВ ГЕПАТИТА А? ОЦЕНКА РЕЗУЛЬТАТОВ ВАКЦИНОПРОФИЛАКТИКИ В ОТДЕЛЬНЫХ РЕГИОНАХ РОССИЙСКОЙ ФЕДЕРАЦИИ

иосиф васильевич шахгильдян,м и михайлов,о н ершова,п а хухлович,в а хасанова,и н лыткина,н и шулакова,в в романенко,а и юровских,а а ясинский

2010引用：22

引用

AI阅读

5Is routine vaccination against hepatitis a needed in children? evaluation of prophylaxis with vaccines in several regions of russian federation

I.V. Shakhgil’dyan, M.I. Mikhaylov, N.I. Ershova,P.A. Khukhlovich,V.A. Khasanova,I.N. Lytkina,N.I. Shulakova,V.V. Romanenko, A.I. Yurovskih, A.A. Yasinskiy

The article presents data on effectiveness of routine vaccination against hepatitis A in children. The results of program of specific prophylaxis of hepatitis A in several regions of Russian Federation are analyzed. Perspectives of implementation of obtained experience are discussed.Key words: children, hepatitis A, routine vaccination, regional vaccination calendars.(Voprosy sovremennoi pediatrii — Current Pediatrics. 2010;9(6):123-126)

2010Voprosy Sovremennoj Pediatrii（2010）

引用

AI阅读

6Результаты Изучения Эффективности Массовой Вакцинопрофилактики Гепатита В В Отдельных Регионах Российской Федерации

И В Шахгильдян,П А Хухлович,О Н Ершова,В А Хасанова, Надежда Александровна Сергеева,Л Е Кузина,Д М Брагинский,И Н Лыткина,Н И Шулакова, В. В. Романенко, В. В. Патлусова, Е В Сармометов,

2010Biological Products Prevention Diagnosis Treatment（2010）

引用

AI阅读

7Нужна Ли В Настоящее Время Плановая Вакцинация Детей Против Гепатита А? Оценка Результатов Вакцинопрофилактики В Отдельных Регионах Российской Федерации

2010Вопросы современной педиатрии

引用

AI阅读

8ЭПИДЕМИОЛОГИЧЕСКАЯ ХАРАКТЕРИСТИКА ХРОНИЧЕСКИХ ГЕПАТИТОВ В И С В РОССИЙСКОЙ ФЕДЕРАЦИИ

И В Шахгильдян,А. А. Ясинский,М. И. Михайлов,О Н Ершова,П А Хухлович,В А Хасанова,И Н Лыткина,Н И Шулакова, В. В. Романенко, В. В. Патлусова,Т. В. Коленова,Н. Д. Ооржак,

2008Мир вирусных гепатитов引用：1

引用

AI阅读

9Современные Эпидемиологические Особенности И Состояние Вакцинопрофилактики Гепатита В В Российской Федерации

И В Шахгильдян,М. И. Михайлов,П А Хухлович,О Н Ершова,В А Хасанова,А. А. Ясинский, Г. С. Коршунова,И Н Лыткина,Н И Шулакова,И А Храпунова, В. В. Романенко, В. В. Патлусова,

2005Детские инфекции

引用

AI阅读

10[The Vaccinal Prophylaxis of Hepatitis B among Children Born to Mothers with Persistent HBs-antigenemia].

P A Khukhlovich,I V Shakhgil'dian,M I Narkevich, V A Anan'ev,S N Kuzin,N A Sergeeva,Sh Kh Khodzhaev,P I Iarovoĭ,Zh A Drobeniuk, A K Iuldashev,M A Khodzhaeva,O N Makmudova,

In Uzbekistan and Moldova 542 children born of HBsAg carriers were immunized against hepatitis B (with vaccine Engerix B according to the immunization schedule of 4 injections). Anti-HBs antibodies in protective titers were detected by EIA and RIA techniques in 76.7% of children aged 4-5 months after the 3rd injection, in 95.7% of children aged 15-16 months and in 90.0% of children aged 2-2.5 years after the 4th (booster) injection. In the control group (117 nonimmunized children born of HBs carriers) observed during the same period anti-HBs antibodies were detected significantly less frequently (in 7.3%, 11.6% and 12.9% of these children respectively). 1-2 months after the course of immunization was completed 74.1% of the immunized children had high anti-HBs antibody titers (exceeding 1000 IU/ml) with their subsequent decrease by 2-2.5 years of age. In the control group these figures were 27.1% and 29.0% respectively. The index of immunization effectiveness obtained by the comparison of the hepatitis B morbidity rates in both groups was 7.8. No postvaccinal complications were registered.

1996Zhurnal mikrobiologii, epidemiologii i immunobiologii（1996）引用：25

引用

AI阅读

11The Risk Of Infection With Hepatitis Virus-B And Virus-C Of Medical-Personnel And Patients Of Hemoperfusion-Wards And Vaccinal Prevention Of Hepatitis-B Virus-Infection In These Populations

Iv Shakhgildyan, Pa Khuklovich,Ya Savin,Sn Kuzin,Va Ananyev, Pa Sergeyeva,Va Khasanova, Gd Shosika, V Zien,An Vasilyev, Ld Zhukova, Ia Khrapunova,

Markers of hepatitis B (HBsAg, anti-HBs) and C (anti-HCV) were detected in 1990-1992 by enzyme immunoassay in 1581 medical workers, 230 last-year students of medical schools, 269 patients hospitalized at hemoperfusion wards, and 701 blood donors. Hepatitis B markers were detected in medical workers two times more frequently than in donors (HBsAg in 4.7 and 2.2% of these, respectively, anti-HBS in 26.2 and 14.0%), and anti-HCV were found almost three times more frequently (in 3.1 and 1.1%, respectively). The incidence of these marjers in students of medical schools was the same as in donors. Hepatitis B markers (HBsAg, anti-HBs) were defected in 39.0% of patients of hemoperfusion departments, HBsAg being present in 11.9%, and antiHCV in 25%. A direct relationship was revealed between the incidence of hepatitis B and C markers and duration of treatment at dialysis centers or length of service at therapeutic institutions. Three vaccinations with Engerix B 944 vaccine were administered to 944 medical workers and 162 medical students and four vaccinations in double doses to 40 patients of hemoperfusion centers who had no hepatitis B markers; a month after immunization anti-HBs in protective titers were detected in 91.4, 93.9, and 76.1% of them, respectively, and a year after vaccination these values were 77.2, 82.5, and 53.3%. No cases of hepatitis B, detection of HBsAg, or postvaccination complications in the vacinees were recorded.

1994VOPROSY VIRUSOLOGII（1994）

引用

AI阅读

12[Risk of Infection with Hepatitis B and C Viruses of Medical Workers, Patients in the Hemodialysis Ward, and Vaccine Prophylaxis of Hepatitis B Infection in These Populations].

I V Shakhgil'dian,P A Khukhlovich,E A Savin,S N Kuzin, V A Anan'ev,N A Sergeeva,V A Khasanova,G D Shostka, Z Vu, A N Vasil'ev

Markers of hepatitis B (HBsAg, anti-HBs) and C (anti-HCV) were detected in 1990-1992 by enzyme immunoassay in 1581 medical workers, 230 last-year students of medical schools, 269 patients hospitalized at hemoperfusion wards, and 701 blood donors. Hepatitis B markers were detected in medical workers two times more frequently than in donors (HBsAg in 4.7 and 2.2% of these, respectively, anti-HBs in 26.2 and 14.0%), and anti-HCV were found almost three times more frequently (in 3.1 and 1.1%, respectively). The incidence of these markers in students of medical schools was the same as in donors. Hepatitis B markers (HBsAg, anti-HBs) were detected in 39.0% of patients of hemoperfusion departments, HBsAg being present in 11.9%, and antiHCV in 25%. A direct relationship was revealed between the incidence of hepatitis B and C markers and duration of treatment at dialysis centers or length of service at therapeutic institutions. Three vaccinations with Engerix B 944 vaccine were administered to 944 medical workers and 162 medical students and four vaccinations in double doses to 40 patients of hemoperfusion centers who had no hepatitis B markers; a month after immunization anti-HBs in protective titers were detected in 91.4, 93.9, and 76.1% of them, respectively, and a year after vaccination these values were 77.2, 82.5, and 53.3%. No cases of hepatitis B, detection of HBsAg, or postvaccination complications in the vaccines were recorded.

1994Voprosy virusologii（1994）引用：40

引用

AI阅读